FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379598412> ?p ?o ?g. }

• W4379598412 endingPage "2601" @default.
• W4379598412 startingPage "2593" @default.
• W4379598412 abstract "Abstract Purpose: The CAPTIVATE study investigated first-line ibrutinib plus venetoclax for chronic lymphocytic leukemia in 2 cohorts: minimal residual disease (MRD)-guided randomized discontinuation (MRD cohort) and Fixed Duration (FD cohort). We report outcomes of fixed-duration ibrutinib plus venetoclax in patients with high-risk genomic features [del(17p), TP53 mutation, and/or unmutated immunoglobulin heavy chain (IGHV)] in CAPTIVATE. Patients and Methods: Patients received three cycles of ibrutinib 420 mg/day then 12 cycles of ibrutinib plus venetoclax (5-week ramp-up to 400 mg/day). FD cohort patients (n = 159) received no further treatment. Forty-three MRD cohort patients with confirmed undetectable MRD (uMRD) after 12 cycles of ibrutinib plus venetoclax received randomized placebo treatment. Results: Of 195 patients with known status of genomic risk features at baseline, 129 (66%) had ≥1 high-risk feature. Overall response rates were &gt;95% regardless of high-risk features. In patients with and without high-risk features, respectively, complete response (CR) rates were 61% and 53%; best uMRD rates: 88% and 70% (peripheral blood) and 72% and 61% (bone marrow); 36-month progression-free survival (PFS) rates: 88% and 92%. In subsets with del(17p)/TP53 mutation (n = 29) and unmutated IGHV without del(17p)/TP53 mutation (n = 100), respectively, CR rates were 52% and 64%; uMRD rates: 83% and 90% (peripheral blood) and 45% and 80% (bone marrow); 36-month PFS rates: 81% and 90%. Thirty-six–month overall survival (OS) rates were &gt;95% regardless of high-risk features. Conclusions: Deep, durable responses and sustained PFS seen with fixed-duration ibrutinib plus venetoclax are maintained in patients with high-risk genomic features, with similar PFS and OS to those without high-risk features. See related commentary by Rogers, p. 2561" @default.
• W4379598412 created "2023-06-08" @default.
• W4379598412 creator A5002467749 @default.
• W4379598412 creator A5005565037 @default.
• W4379598412 creator A5008054206 @default.
• W4379598412 creator A5011559739 @default.
• W4379598412 creator A5013236194 @default.
• W4379598412 creator A5019892839 @default.
• W4379598412 creator A5034517642 @default.
• W4379598412 creator A5035890812 @default.
• W4379598412 creator A5036828560 @default.
• W4379598412 creator A5053787554 @default.
• W4379598412 creator A5055100327 @default.
• W4379598412 creator A5057841284 @default.
• W4379598412 creator A5078620979 @default.
• W4379598412 creator A5085393928 @default.
• W4379598412 creator A5089428686 @default.
• W4379598412 creator A5090615083 @default.
• W4379598412 creator A5092103949 @default.
• W4379598412 date "2023-06-07" @default.
• W4379598412 modified "2023-10-18" @default.
• W4379598412 title "Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia" @default.
• W4379598412 cites W1243376384 @default.
• W4379598412 cites W1429374962 @default.
• W4379598412 cites W2016042196 @default.
• W4379598412 cites W2075875145 @default.
• W4379598412 cites W2140606816 @default.
• W4379598412 cites W2142099365 @default.
• W4379598412 cites W2142741025 @default.
• W4379598412 cites W2153923291 @default.
• W4379598412 cites W2295348655 @default.
• W4379598412 cites W2396328865 @default.
• W4379598412 cites W2580821712 @default.
• W4379598412 cites W2789078984 @default.
• W4379598412 cites W2901396567 @default.
• W4379598412 cites W2947182341 @default.
• W4379598412 cites W3012733259 @default.
• W4379598412 cites W3039488989 @default.
• W4379598412 cites W3045571650 @default.
• W4379598412 cites W3048790590 @default.
• W4379598412 cites W3082899459 @default.
• W4379598412 cites W3095638461 @default.
• W4379598412 cites W3132537256 @default.
• W4379598412 cites W3169739858 @default.
• W4379598412 cites W3200592707 @default.
• W4379598412 cites W3203683811 @default.
• W4379598412 cites W4205825534 @default.
• W4379598412 cites W4206586970 @default.
• W4379598412 cites W4213453359 @default.
• W4379598412 cites W4284883545 @default.
• W4379598412 cites W4291320147 @default.
• W4379598412 doi "https://doi.org/10.1158/1078-0432.ccr-22-2779" @default.
• W4379598412 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37282671" @default.
• W4379598412 hasPublicationYear "2023" @default.
• W4379598412 type Work @default.
• W4379598412 citedByCount "2" @default.
• W4379598412 countsByYear W43795984122023 @default.
• W4379598412 crossrefType "journal-article" @default.
• W4379598412 hasAuthorship W4379598412A5002467749 @default.
• W4379598412 hasAuthorship W4379598412A5005565037 @default.
• W4379598412 hasAuthorship W4379598412A5008054206 @default.
• W4379598412 hasAuthorship W4379598412A5011559739 @default.
• W4379598412 hasAuthorship W4379598412A5013236194 @default.
• W4379598412 hasAuthorship W4379598412A5019892839 @default.
• W4379598412 hasAuthorship W4379598412A5034517642 @default.
• W4379598412 hasAuthorship W4379598412A5035890812 @default.
• W4379598412 hasAuthorship W4379598412A5036828560 @default.
• W4379598412 hasAuthorship W4379598412A5053787554 @default.
• W4379598412 hasAuthorship W4379598412A5055100327 @default.
• W4379598412 hasAuthorship W4379598412A5057841284 @default.
• W4379598412 hasAuthorship W4379598412A5078620979 @default.
• W4379598412 hasAuthorship W4379598412A5085393928 @default.
• W4379598412 hasAuthorship W4379598412A5089428686 @default.
• W4379598412 hasAuthorship W4379598412A5090615083 @default.
• W4379598412 hasAuthorship W4379598412A5092103949 @default.
• W4379598412 hasBestOaLocation W43795984121 @default.
• W4379598412 hasConcept C126322002 @default.
• W4379598412 hasConcept C143998085 @default.
• W4379598412 hasConcept C2777609679 @default.
• W4379598412 hasConcept C2777938653 @default.
• W4379598412 hasConcept C2778461978 @default.
• W4379598412 hasConcept C2778715236 @default.
• W4379598412 hasConcept C2779675984 @default.
• W4379598412 hasConcept C2779878957 @default.
• W4379598412 hasConcept C71924100 @default.
• W4379598412 hasConcept C72563966 @default.
• W4379598412 hasConcept C90924648 @default.
• W4379598412 hasConceptScore W4379598412C126322002 @default.
• W4379598412 hasConceptScore W4379598412C143998085 @default.
• W4379598412 hasConceptScore W4379598412C2777609679 @default.
• W4379598412 hasConceptScore W4379598412C2777938653 @default.
• W4379598412 hasConceptScore W4379598412C2778461978 @default.
• W4379598412 hasConceptScore W4379598412C2778715236 @default.
• W4379598412 hasConceptScore W4379598412C2779675984 @default.
• W4379598412 hasConceptScore W4379598412C2779878957 @default.
• W4379598412 hasConceptScore W4379598412C71924100 @default.
• W4379598412 hasConceptScore W4379598412C72563966 @default.
• W4379598412 hasConceptScore W4379598412C90924648 @default.

• next